Home/Filings/4/0001860008-25-000009
4//SEC Filing

Telman Deborah H 4

Accession 0001860008-25-000009

CIK 0000882095other

Filed

Nov 12, 7:00 PM ET

Accepted

Nov 13, 7:36 PM ET

Size

18.8 KB

Accession

0001860008-25-000009

Insider Transaction Report

Form 4
Period: 2025-11-12
Telman Deborah H
EVP, Corporate Affairs & GC
Transactions
  • Exercise/Conversion

    Non-qualified Stock Option (Right to Buy)

    2025-11-1217,18137,799 total
    Exercise: $75.12Exp: 2034-03-10Common Stock (17,181 underlying)
  • Sale

    Common Stock

    2025-11-12$122.30/sh35,965$4,398,59143,676 total
  • Sale

    Common Stock

    2025-11-12$122.90/sh500$61,45243,676 total
  • Exercise/Conversion

    Non-qualified Stock Option (Right to Buy)

    2025-11-1235,96512,655 total
    Exercise: $60.75Exp: 2032-07-25Common Stock (35,965 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-12$75.12/sh+17,181$1,290,63760,857 total
  • Exercise/Conversion

    Common Stock

    2025-11-12$60.75/sh+35,965$2,184,87479,641 total
  • Exercise/Conversion

    Non-qualified Stock Option (Right to Buy)

    2025-11-1250012,155 total
    Exercise: $60.75Exp: 2032-07-25Common Stock (500 underlying)
  • Sale

    Common Stock

    2025-11-12$124.00/sh17,181$2,130,44443,676 total
  • Exercise/Conversion

    Common Stock

    2025-11-12$60.75/sh+500$30,37544,176 total
Footnotes (4)
  • [F1]The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
  • [F2]Sales prices for the transactions reported here range from $121.87 to $122.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  • [F3]Sales prices for the transactions reported here range from $122.88 to $122.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  • [F4]The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Issuer

GILEAD SCIENCES, INC.

CIK 0000882095

Entity typeother

Related Parties

1
  • filerCIK 0001860008

Filing Metadata

Form type
4
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 7:36 PM ET
Size
18.8 KB